JORGE GUERRERO | AFP via Getty Images

About six weeks after the Food and Drug Administration approved the first cholesterol pill in the PCSK9 class, the practical question for patients has shifted from whether the drug works to what it costs and whether insurance will pay for it. Lipfendra, known generically as enlicitide, is now stocked at retail and mail-order pharmacies, and the cash price is where most households will first encounter it.

Merck set a list price of $315 for a 30-day supply. Cash prices at major chains sit close to that figure. GoodRx lists an average retail price near $382, with discounted prices at individual pharmacies running from about $309 to $356. Over a year, the list price works out to roughly $3,780 before insurance, discounts or copay assistance.

For a patient who has declined injectable therapy because of needles, refrigeration, or specialty pharmacy requirements, that number is the new decision point. It is also the number most likely to determine whether the pill actually changes anything for the people it was designed to reach.

The Pill Is Real and So Is the Price Tag

Lipfendra is a once-daily 20-milligram tablet taken in the morning on an empty stomach, with a 30-minute wait before eating. It can be stored at room temperature and does not require dose titration or a specialty pharmacy, which is the operational difference from the injectables.

Every previously approved PCSK9 inhibitor has been an injection. Evolocumab and alirocumab are self-administered every two to four weeks. Inclisiran, which reaches the same pathway differently, is given by a clinician roughly twice a year after initial doses.

MedicalDaily previously reported on the approval of the first oral PCSK9 inhibitor and on who the pill was approved for. The clinical picture has not changed since. What has changed is that the drug is now something a pharmacist can actually quote a price on.

The Evidence Behind the Approval

The approval rested on two randomized, double-blind, placebo-controlled trials enrolling 3,207 adults already on maximally tolerated statin therapy. According to the FDA approval announcement, the first trial enrolled adults with established or high risk of atherosclerotic cardiovascular disease and showed an average 56 percent LDL reduction at week 24 compared with placebo. The second enrolled adults with heterozygous familial hypercholesterolemia and showed a 59 percent reduction.

Those figures are placebo-adjusted percentage changes in LDL cholesterol, which is a laboratory measure and a well-established risk factor. They are not heart attack or stroke outcomes. Neither approval trial was designed to show that this pill prevents cardiovascular events.

That question is being tested. A separate outcomes trial, CORALreef Outcomes, has enrolled more than 14,500 participants at high cardiovascular risk and is measuring time to a first major cardiovascular event. Its estimated primary completion date is late 2029, so no outcomes results are expected for years.

Adverse reactions in the first trial were similar between the drug and placebo groups. In the familial hypercholesterolemia trial, diarrhea and dizziness occurred more often with the drug. Discontinuation rates for adverse reactions were comparable across both.

Michael Davis, acting director of the FDA's Center for Drug Evaluation and Research, said in the agency's announcement that "elevated LDL cholesterol is one of its most important modifiable risk factors" for cardiovascular disease. Merck Research Laboratories president Dean Li called the approval a pivotal moment in the company's own announcement. Both statements come from parties with an interest in the product.

Coverage Is the Variable That Decides Most Households

List price is not what most insured patients pay, but it sets the ceiling and the negotiating floor. Several coverage questions are worth raising with a prescriber or pharmacist before assuming a switch is straightforward.

Most insurers require a documented statin trial before approving any PCSK9 inhibitor. Formulary placement determines the copay tier, and plans that added the drug mid-year may not have published tier assignments yet. Patients who are already stable on an injectable and paying little out of pocket may find the pill costs more, not less, depending on their plan's arrangement with the injectable manufacturer.

Medicare Part D enrollees have an annual out-of-pocket cap, which changes the arithmetic substantially for a medication taken indefinitely. Commercial plan members can ask about manufacturer copay cards, which typically exclude patients covered by government insurance.

The people most likely to benefit are the ones who never started a PCSK9 inhibitor at all: patients who declined injections, patients who could not manage specialty pharmacy logistics, and high-risk patients in areas where specialty pharmacy access is limited. In large metro areas including Houston, Phoenix, Detroit, and Miami, where a meaningful share of adults are uninsured or underinsured, cash price will determine access regardless of clinical fit.

Questions Worth Asking Before Switching

No one taking a statin, ezetimibe, or an injectable PCSK9 inhibitor should stop or change a prescription based on a news article. LDL targets, cardiovascular history, and prior medication tolerance all shape whether a switch makes sense, and that conversation belongs with a clinician.

Patients considering the pill can ask three practical questions. What is the plan's tier and prior authorization requirement? What is the actual copay compared with the current regimen? And whether the empty-stomach dosing requirement is workable given existing morning medications.

Patients facing a denial can ask about appeals, prior authorization documentation, and patient assistance programs. Community health centers and hospital financial counselors can also help with lipid testing and medication access for uninsured patients, and many run sliding-scale pricing.

Anyone starting the pill will still need periodic lipid panels to confirm it is working, and those visits carry their own costs. Building that into the budget conversation up front avoids a surprise later.

Whether broader coverage follows remains open. Merck has said it plans to offer the drug through a direct-to-patient channel but has not published pricing for it. MedicalDaily will track formulary decisions and any outcomes data.

Key Questions Answered

What does the pill cost? The list price is $315 for a 30-day supply. Discounted cash prices at major chains have run roughly $309 to $356, and insured cost depends on plan tier and deductible status.

Who is it approved for? Adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia, as an addition to diet and exercise.

How well does it lower LDL? In the two approval trials, LDL fell an average of 56 percent and 59 percent compared with placebo at week 24, in patients already on maximally tolerated statins.

Does it prevent heart attacks? That has not been shown. The approval trials measured LDL reduction, not cardiovascular events. A separate outcomes trial is running, with completion estimated for late 2029.

What are the side effects? In the familial hypercholesterolemia trial, diarrhea and dizziness occurred more often than with placebo. In the larger trial, adverse reactions were comparable to placebo.

Will insurance cover it? Coverage varies. Most plans require a documented statin trial first, and some have not yet published formulary placement.

Should someone on an injectable switch? That is a decision for a clinician. No one should stop or change a prescribed cholesterol medication without medical guidance.

Originally published on Medical Daily